Qifu Xu

发表

Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.

Yingjie Zhang, Chunxi Liu, Qin'ge Ding, 2020, Bioorganic chemistry.

In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK‐875

Wenfang Xu, Yingjie Zhang, Yugang Yan, 2020, Drug development research.

Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Yingjie Zhang, Chunlong Zhao, Hang Dong, 2020, Expert opinion on therapeutic patents.

Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021)

Qifu Xu, Qian Liu, Shunda Li, 2022, Expert opinion on therapeutic patents.

Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent

Yingjie Zhang, C. Chou, J. Zang, 2020, Frontiers in Cell and Developmental Biology.

Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis

Yingjie Zhang, Jiangying Cao, Chunlong Zhao, 2021, RSC advances.

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.

Yingjie Zhang, Chunlong Zhao, Wei Zhao, 2021, Bioorganic chemistry.

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.

Yu Zhou, Min Huang, M. Geng, 2021, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Yingjie Zhang, Hang Dong, Wei Zhao, 2021, ACS medicinal chemistry letters.